Developing Drugs with Genetic Chemistry
Founded in 2004, Evolva has three main attributes:
- A unique technology platform that creates small molecule drugs from genetics – with 80$ million of 3rd party funding to Evolva and our partners for discovery programs that utilize the platform.
- An attractive pipeline of potential pharmaceutical products deriving from this approach - one (a thromboxane receptor antagonist for cardiovascular and/or kidney disease) entered Phase I beginning of 2009, the second (anti-fungal) is expected to enter Phase I beginning of 2010.
- An experienced team, following an aggressive, pragmatic, cost-effective and international business model, with operations in Switzerland, India, Denmark and the USA.
Over the next three years we aim to further develop our compound pipeline and technology base to a level of maturity that enables us to seek a public listing of our shares.
Evolva News
18th March, 2009
Evolva starts Phase I Clinical Trials on EV-077
6th January, 2009